Literature DB >> 23276468

Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure.

Wayne L Miller1, Diane E Grill, Joachim Struck, Allan S Jaffe.   

Abstract

Baseline values, serial measurements, or both of multiple biomarkers (copeptin, a peptide co-secreted with arginine vasopressin; hyponatremia; B-type natriuretic peptide [BNP]; and cardiac troponin T [cTnT]) may improve risk stratification in outpatients with chronic heart failure. A cohort of 157 patients with class III or IV heart failure was prospectively evaluated every 3 months over 2 years with regard to biomarker levels and risk for death or cardiac transplantation. Copeptin ≥40 pmol/L (cohort fourth quartile value), hyponatremia (≤135 mEq/L), BNP >3 times the upper range limitation of normal adjusted for age and gender, and cTnT ≥0.01 ng/ml were pre hoc determined cut points. After multivariate time-dependent regression analysis, copeptin (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.2 to 4.3, p = 0.014) and BNP (HR 1.89, 95% CI 1.0 to 3.5, p = 0.047), but not hyponatremia, were associated with the primary end point of death or cardiac transplantation. In contrast to univariate prediction of mortality and transplantation, hyponatremia (HR 1.74, 95% CI 0.9 to 3.4, p = 0.099) and cTnT ≥0.01 ng/ml (HR 1.89, 95% CI 1.0 to 3.7, p = 0.064) were not predictive in multivariate models. Interaction models of copeptin with hyponatremia, adjusted for BNP and cTnT, improved the predictive capacity of serial measurements (HR 4.20, 95% CI 1.6 to 8.9, p = 0.004). In conclusion, marked elevations of copeptin, particularly in serial measurements, are independent predictors of poor outcomes. The combination of elevated copeptin with hyponatremia, when adjusted for BNP and cTnT, is an even stronger predictor. These markers appear to reflect activation of the arginine vasopressin system present even in the absence of overt clinical changes. A strategy of serial monitoring of copeptin in combination with hyponatremia may be valuable in identifying higher risk patients with heart failure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23276468     DOI: 10.1016/j.amjcard.2012.11.053

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Hyponatremia in the outpatient setting: clinical characteristics, risk factors, and outcome.

Authors:  Vildan Tasdemir; Ali Kemal Oguz; Irmak Sayın; Ihsan Ergun
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

2.  Unraveling the relationship between mortality, hyponatremia, inflammation and malnutrition in hemodialysis patients: results from the international MONDO initiative.

Authors:  M J E Dekker; D Marcelli; B Canaud; C J A M Konings; K M Leunissen; N W Levin; P Carioni; V Maheshwari; J G Raimann; F M van der Sande; L A Usvyat; P Kotanko; J P Kooman
Journal:  Eur J Clin Nutr       Date:  2016-04-20       Impact factor: 4.016

Review 3.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

4.  Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.

Authors:  Annarein J C Kerbert; Len Verbeke; Fang W T Chiang; Wim Laleman; Johan J van der Reijden; Wim van Duijn; Frederik Nevens; Ron Wolterbeek; Bart van Hoek; Hein W Verspaget; Minneke J Coenraad
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

Review 5.  Biomarkers in heart failure: the importance of inconvenient details.

Authors:  Wayne L Miller; Allan S Jaffe
Journal:  ESC Heart Fail       Date:  2015-11-25

6.  Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis.

Authors:  Peng Zhang; Xiaomei Wu; Guangxiao Li; Hao Sun; Jingpu Shi
Journal:  Ther Clin Risk Manag       Date:  2017-01-05       Impact factor: 2.423

7.  Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis.

Authors:  Jian-Jun Yan; Ying Lu; Zheng-Ping Kuai; Yong-Hong Yong
Journal:  J Cell Mol Med       Date:  2017-02-28       Impact factor: 5.310

8.  Risk stratification in emergency patients by copeptin.

Authors:  Kasper Iversen; Jens P Gøtze; Morten Dalsgaard; Henrik Nielsen; Søren Boesgaard; Morten Bay; Vibeke Kirk; Olav W Nielsen; Lars Køber
Journal:  BMC Med       Date:  2014-05-16       Impact factor: 8.775

9.  Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.

Authors:  Paul Welsh; Lei Kou; Changhong Yu; Inder Anand; Dirk J van Veldhuisen; Aldo P Maggioni; Akshay S Desai; Scott D Solomon; Marc A Pfeffer; Sunfa Cheng; Lars Gullestad; Pål Aukrust; Thor Ueland; Karl Swedberg; James B Young; Michael W Kattan; Naveed Sattar; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2017-09-27       Impact factor: 15.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.